Press Releases MaaT Pharma Annonce 18 millions d’euros de Financement Série B pour l’Expansion de son Développement Clinique de Médicaments Biologiques « Microbiote » Lyon, le 5 février 2020 - MaaT Pharma annonce aujourd'hui une levée de fonds de…nboutaouiFebruary 4, 2020
Press Releases MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B…nboutaouiJanuary 31, 2020
Press Releases MaaT Pharma announces the presentation of data with its Lead Microbiota Biotherapeutic in intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting Lyon, France, November 6, 2019 – MaaT Pharma announced today that a poster will…nboutaouiNovember 6, 2019
Press Releases MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform GutPrint Jean-Marc Renard, MS, MBA, joins as Chief Business Officer Emmanuel Prestat, PhD, joins as Computational…nboutaouiSeptember 10, 2019
Press Releases MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…nboutaouiJune 24, 2019
Press Releases MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform - First patents to cover the fundamental processes for accessing the human gut microbiome as…nboutaouiMay 21, 2019
Press Releases IMM-ETG – A New European Initiative for Intestinal Microbiome Medicinal Products “Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute…nboutaouiMay 21, 2019
Press Releases MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute…nboutaouiApril 9, 2019
Press Releases MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification. Lyon, France,…nboutaouiFebruary 5, 2019
Press Releases MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting Data show achievement of primary endpoint, demonstration of functional microbiota restoration, inflammation reduction and positive…nboutaouiDecember 2, 2018